Compare Alcon AG (ALC) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Bank of Montreal — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Bank of Montreal trades at $174.51 (market cap $124.94B). The key difference: Bank of Montreal is far larger — about 3.8× Alcon AG's market cap, and Bank of Montreal pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| ALC | BMO | |
|---|---|---|
Market Cap | $32.69B | $124.94B |
Sector | Health | Financials |
52-Week High | $92.22 | $178.25 |
52-Week Low | $62.02 | $110.44 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BMO trades at $178.25, up 2.37% today, with a bullish technical signal and strong analyst support. Recent earnings show a mixed record with a Q1 2026 miss but beats in prior quarters, while revenue and net income have grown steadily. The company maintains a solid dividend history and was recently recognized as Best Commercial Bank in Canada and the U.S. by World Finance Magazine (June 23, 2026).
The outlook is positive given earnings growth and strategic acquisitions, but risks include valuation above historical averages and sensitivity to interest rates. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism for continued performance amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
